H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (INSM) today and set a price target of $43. The company’s shares closed on Friday at $24.79.
Fein commented:
“Our price target of $43/share is based on: (a) $40/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.04 discounted back to and (b) an NPV of $47/share (discount rate 12.0%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.3% and a 46.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $41.50, a 67.4% upside from current levels. In a report issued on January 15, Canaccord Genuity also reiterated a Buy rating on the stock with a $32 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.58 and a one-year low of $11.31. Currently, Insmed has an average volume of 1.05M.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INSM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.
